Q4 2018 EPS Estimates for Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Decreased by Piper Jaffray Companies

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) – Piper Jaffray Companies lowered their Q4 2018 earnings estimates for Supernus Pharmaceuticals in a note issued to investors on Tuesday, July 24th, Zacks Investment Research reports. Piper Jaffray Companies analyst D. Amsellem now forecasts that the specialty pharmaceutical company will post earnings per share of $0.50 for the quarter, down from their prior estimate of $0.51. Piper Jaffray Companies currently has a “Hold” rating and a $44.00 target price on the stock.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.43 by $0.14. Supernus Pharmaceuticals had a return on equity of 30.57% and a net margin of 24.17%. The company had revenue of $99.54 million during the quarter, compared to analysts’ expectations of $101.01 million.

SUPN has been the subject of a number of other reports. ValuEngine upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 12th. Zacks Investment Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Saturday, May 5th. BidaskClub upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 16th. Stifel Nicolaus boosted their price target on Supernus Pharmaceuticals from $50.00 to $60.00 and gave the company a “buy” rating in a report on Friday, May 25th. Finally, Jefferies Financial Group boosted their price target on Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a report on Thursday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $54.09.

Shares of Supernus Pharmaceuticals opened at $46.15 on Thursday, according to Marketbeat.com. Supernus Pharmaceuticals has a twelve month low of $33.30 and a twelve month high of $61.25. The company has a quick ratio of 4.74, a current ratio of 2.74 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $2.52 billion, a PE ratio of 36.63 and a beta of 0.97.

In related news, CFO Gregory S. Patrick sold 35,000 shares of the company’s stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $56.63, for a total transaction of $1,982,050.00. Following the completion of the transaction, the chief financial officer now directly owns 75,975 shares in the company, valued at approximately $4,302,464.25. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Padmanabh P. Bhatt sold 7,205 shares of the company’s stock in a transaction on Thursday, June 21st. The stock was sold at an average price of $60.00, for a total value of $432,300.00. Following the transaction, the vice president now owns 14,705 shares of the company’s stock, valued at $882,300. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 117,868 shares of company stock valued at $6,600,620. 6.20% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of SUPN. BlackRock Inc. grew its stake in shares of Supernus Pharmaceuticals by 8.7% in the second quarter. BlackRock Inc. now owns 7,690,669 shares of the specialty pharmaceutical company’s stock worth $460,287,000 after purchasing an additional 618,722 shares in the last quarter. Summit Trail Advisors LLC grew its stake in shares of Supernus Pharmaceuticals by 4,144.2% in the first quarter. Summit Trail Advisors LLC now owns 1,617,365 shares of the specialty pharmaceutical company’s stock worth $1,617,000 after purchasing an additional 1,579,257 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Supernus Pharmaceuticals by 0.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,403,994 shares of the specialty pharmaceutical company’s stock worth $64,303,000 after purchasing an additional 4,844 shares in the last quarter. Champlain Investment Partners LLC grew its stake in shares of Supernus Pharmaceuticals by 5.1% in the first quarter. Champlain Investment Partners LLC now owns 1,275,155 shares of the specialty pharmaceutical company’s stock worth $58,402,000 after purchasing an additional 62,370 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of Supernus Pharmaceuticals by 6.8% in the second quarter. Wells Fargo & Company MN now owns 957,210 shares of the specialty pharmaceutical company’s stock worth $57,290,000 after purchasing an additional 61,100 shares in the last quarter. Hedge funds and other institutional investors own 98.01% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Further Reading: Book Value Per Share in Stock Trading

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply